Gait initiation in multiple sclerosis patients with and without functional loss - Salamci M, Salc ı Y, Topuz S, Yalçın A, Acar Özen P, Tuncer A.
BACKGROUND: Gait initiation (GI) is an important functional task related to balance and gait performance. In addition, it has predictive importance for falls and postural instability in patient with multiple sclerosis (MS). However, it is uncertain how GI ... (Source: SafetyLit)
Source: SafetyLit - September 20, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Reliability and validity of the Fullerton Advanced Balance Scale in people with multiple sclerosis - Özbaş E, Balkan AF, Salcı Y, Tuncer A.
This study was conducted to evaluate the reliability and validity of the Fullerton Advanced Balance Scale (FAB) in people with Multiple Sclerosis (PwMS). METHODS: A total of 65 people with multiple sclerosis, Expanded Disability Status Sca... (Source: SafetyLit)
Source: SafetyLit - September 19, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Links between neuroanatomy and neurophysiology with turning performance in people with multiple sclerosis - Swanson CW, Fling BW.
Multiple sclerosis is accompanied by decreased mobility and various adaptations affecting neural structure and function. Therefore, the purpose of this project was to understand how motor cortex thickness and corticospinal excitation and inhibition contrib... (Source: SafetyLit)
Source: SafetyLit - September 18, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
New Evidence Early Tx Improves Preclinical MS Outcomes New Evidence Early Tx Improves Preclinical MS Outcomes
The disease-modifying drug teriflunomide reduces the risk of developing clinical multiple sclerosis by 72% in radiologically isolated syndrome.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 13, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Gene Test Spots Those Vulnerable to Rare but Severe Side Effect of Drugs for MS, Other Conditions
WEDNESDAY, Sept. 13, 2023 -- A large number of drugs used to treat everything from multiple sclerosis to blood cancers to rheumatoid arthritis may cause a rare but often-fatal condition called progressive multifocal leukoencephalopathy (PML).
But a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 13, 2023 Category: General Medicine Source Type: news
The Quest to Solve MS: 'It's a Story That's Optimistic'
(MedPage Today) -- Credit: UCSF Medical Center
"I think primarily this is a story of discovery," said neurologist and multiple sclerosis (MS) researcher Stephen Hauser, MD, of the University of California San Francisco, about his book, The... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 8, 2023 Category: American Health Source Type: news
Vaccines Not Linked to MS Flare-Ups
(MedPage Today) -- Getting vaccinated wasn't tied to an uptick in multiple sclerosis (MS) flare-ups in a large national study from France.
Hospitalization for an MS flare showed no hint of increased likelihood in the 60 days after exposure to... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - September 5, 2023 Category: Infectious Diseases Source Type: news
Multiple sclerosis: Mum hopes groundbreaking trial helps her MS
Lisa Haines uses a scooter and walking stick to get about and hopes a multiple sclerosis pilot helps. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 5, 2023 Category: Consumer Health News Source Type: news
Multiple sclerosis medication could potentially treat Alzheimer's disease, study suggests, and the approved drug could be available to patients immediately
Researchers discovered that ponesimod, a drug already approved by the US Food and Drug Administration (FDA) to treat relapsing forms of MS, reduces inflammation in the brain. (Source: the Mail online | Health)
Source: the Mail online | Health - September 4, 2023 Category: Consumer Health News Source Type: news
European Commission approves Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth1Approval is based on interim data from ongoing RAINBOWFISH trial showing majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment2,3Evrysdi is the only non-invasive SMA therapy and is approved in 100 countries with more than 11,000 patients treated globallyBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved the extension of the Evrysdi ® (risdiplam) European Union (EU) marketing ...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth1Approval is based on interim data from ongoing RAINBOWFISH trial showing majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment2,3Evrysdi is the only non-invasive SMA therapy and is approved in 100 countries with more than 11,000 patients treated globallyBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved the extension of the Evrysdi ® (risdiplam) European Union (EU) marketing ...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news
Novartis' knockoff of Biogen's Tysabri is first MS biosim in US
Two months after a federal court in Delaware rejected Biogen’s patent infringement c | The FDA has endorsed Novartis' Tyruco as the first U.S. biosimilar to treat multiple sclerosis. The copycat will compete with Biogen's Tysabri, covering all of the original drug's indications for relapsing MS in…#delaware #biogen #fda #novartis #tysabri #crohn (Source: Reuters: Health)
Source: Reuters: Health - August 27, 2023 Category: Consumer Health News Source Type: news
'Doctors said I was drunk, but I had multiple sclerosis'
The mum-of-one is now calling for better support for MS patients. (Source: Daily Express - Health)
Source: Daily Express - Health - August 26, 2023 Category: Consumer Health News Source Type: news
First Biosimilar, Tyruko, Approved to Treat Multiple Sclerosis
FRIDAY, Aug. 25, 2023 -- The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of multiple sclerosis, the agency announced... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 25, 2023 Category: General Medicine Source Type: news
FDA Okays First Biosimilar for Multiple Sclerosis FDA Okays First Biosimilar for Multiple Sclerosis
Sandoz ' s natalizumab-sztn injection (Tyruko) is on par with Biogen ' s Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA said in approving the first biosimilar to treat MS.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 25, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
